Maximize Your Portfolio with Data Driven Insights:
- Leverage the power of TipRanks' Smart Score, a data-driven tool to help you uncover top performing stocks and make informed investment decisions.
- Monitor your stock picks and compare them to top Wall Street Analysts' recommendations with Your Smart Portfolio
Purple Biotech ( (PPBT) ) has provided an announcement.
Purple Biotech announced on February 3, 2025, its collaboration with the Icahn School of Medicine at Mount Sinai to explore the immunoregulation of NK and T cells within the tumor microenvironment using its CAPTN-3 tri-specific antibody platform. This partnership aims to deepen the understanding of CAPTN-3’s mechanisms and could enhance tumor-specific immunity against multiple cancer types, potentially leading to improved responses in resistant cancer patients. This collaboration reflects the growing interest in multi-specific engagers and positions Purple Biotech to advance CAPTN-3 towards human clinical studies, which may pave the way for effective treatments for challenging tumor indications.
More about Purple Biotech
Purple Biotech Ltd. is a clinical-stage company focused on developing first-in-class therapies that address tumor immune evasion and drug resistance. The company’s oncology pipeline includes CM24, NT219, and CAPTN-3, with CM24 and NT219 having shown promising results in early clinical studies. Based in Rehovot, Israel, Purple Biotech is advancing its CAPTN-3 platform, which engages both T cells and NK cells to enhance immune responses within the tumor microenvironment.
YTD Price Performance: -29.19%
Average Trading Volume: 969,185
Technical Sentiment Consensus Rating: Hold
Current Market Cap: $8.88M
Find detailed analytics on PPBT stock on TipRanks’ Stock Analysis page.
